P
REGN icon

&Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

&Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.18M Buy
5,404
+551
+11% +$422K 0.02% 585
2025
Q4 		$3.75M Buy
4,853
+1,387
+40% +$942K 0.02% 602
2025
Q3 		$1.96M Sell
3,466
-384
-10% -$217K 0.01% 763
2025
Q2 		$2.06M Sell
3,850
-2,272
-37% -$1.27M 0.02% 656
2025
Q1 		$3.91M Buy
6,122
+740
+14% +$509K 0.04% 348
2024
Q4 		$3.88M Buy
5,382
+3,440
+177% +$2.89M 0.05% 323
2024
Q3 		$2.04M Buy
1,942
+1,345
+225% +$1.5M 0.04% 363
2024
Q2 		$627K Buy
+597
New +$579K 0.03% 466

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

&Partners's REGN Position: Q1 2026 in Review

&Partners increased its Regeneron Pharmaceuticals (REGN) stake by 11% in Q1 2026, buying an estimated $422K and bringing the position to 5,404 shares worth $4.18M. The position accounts for 0.02% of the portfolio, ranked #585.

&Partners first reported a position in REGN in Q2 2024 and has held it in 8 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • &Partners held 5,404 shares of Regeneron Pharmaceuticals worth $4.18M as of Q1 2026.
  • &Partners bought 551 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $422K.
  • Regeneron Pharmaceuticals made up 0.02% of &Partners's portfolio in Q1 2026, its #585 holding.
  • &Partners first reported a position in Regeneron Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.